Table 4. Treatment administered to study participants by type of metastasis, n (%).

CDK4/6-i: CDK4/6 inhibitors; EC: epirubicin and cyclophosphamide; HT: hormone therapy; RT: radiotherapy; SLNB: selective lymph node biopsy.

Variables	Overall (n = 17)	Oligometastatic (n = 12)	Multimetastatic (n = 5)
Initial systemic treatment
EC + Taxanes	4 (24)	4 (33)	0 (0)
EC + Taxanes + Carboplatin	1 (6)	1 (8)	0 (0)
EC + Taxanes + Anti-HER2	2 (12)	2 (17)	0 (0)
Taxanes + Anti-HER2	4 (24)	1 (8)	3 (60)
HT	1 (6)	0 (0)	1 (20)
HT + CDK4/6-i	5 (29)	4 (33)	1 (20)
Local ablative treatment
Primary
Tumourectomy	2 (12)	0 (0)	2 (40)
Tumourectomy + SLNB	2 (12)	2 (17)	0 (0)
Tumourectomy + Lymphadenectomy	3 (18)	3 (25)	0 (0)
Mastectomy + SLNB	1 (6)	1 (8)	0 (0)
Mastectomy + Lymphadenectomy	7 (41)	5 (42)	2 (40)
RT	2 (12)	1 (8)	1 (20)
Metastatic
None	9 (53)	5 (42)	4 (80)
RT bone M1	5 (29)	5 (42)	0 (0)
RT nodal M1	2 (12)	1 (8)	1 (20)
RT nodal and bone M1	1 (6)	1 (8)	0 (0)
Adjuvant treatment
RT	6 (35)	5 (42)	1 (20)
RT + Anti-HER2	1 (6)	0 (0)	1 (20)
RT + HT	2 (12)	2 (17)	0 (0)
HT	2 (12)	2 (17)	0 (0)
RT + Anti-HER2 + HT	1 (6)	1 (8)	0 (0)
None	5 (29)	2 (17)	3 (60)